The news: GLP-1 drugmakers unveiled a wave of new clinical data at the recent American Diabetes Association's annual meeting, highlighting next-generation obesity and diabetes treatments.

• Eli Lilly: Reinforced earlier findings of roughly 30% average weight loss for its triple-action candidate retatrutide, alongside improvements blood sugar control osteoarthritis pain, and sleep apnea.
• Novo Nordisk: New data for CagriSema, now under review at the FDA, showed around a two percentage point reduction in blood sugar levels for type 2 diabetes. It also said Wegovy surpassed 3 million prescriptions this month.
• Roche: Midstage trial data showed its once-weekly injectable enicepatide delivered 22.7% average weight loss after 48 weeks.
• Pfizer: Its monthly obesity injectable berobenatide, which was acquired through Pfizer's $10 billion Metsera deal, produced 10% to 16% weight loss in midstage studies, depending on dose and treatment duration.
• AstraZeneca: Its oral GLP-1 candidate elecoglipron generated 11% to 12% weight loss in midstage trials and is advancing into late-stage testing.

Why it matters: The GLP-1 market remains driven by weight loss efficacy. Companies tout the weight loss achieved by drug candidates in clinical trials, and even a few percentage points can sway investor sentiment and market reaction.

The expanded market of GLP-1 drugmakers will have a massive population of patients expected to seek these medications. GLP-1 prescriptions have nearly tripled since 2021, according to Epic Research Q1 data. Another 42% of US adults who are overweight but not currently taking a GLP-1 say they're likely to start one this year, according to a January survey from Sunlight.com.

Implications for GLP-1 marketers: As obesity treatment evolves into a large chronic-care market, pharma companies are likely to invest heavily to commercialize their products to support long product cycles as they compete for market share. That means new disease-awareness campaigns that reinforce and destigmatize obesity as a chronic condition to encourage new patients to seek treatment. Meanwhile, brand marketing will need to focus on differentiating products based on clinical outcomes, cost, convenience, and other lifestyle benefits. As more therapies reach the market, differentiation will depend on how effectively drugmakers communicate those benefits to specific patient segments and their physicians.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.